In vitro activity of cefpirome and vancomycin in combination against gentamicin-susceptible and gentamicin-resistant Staphylococcus aureus  by Carricajo, A. et al.
CONCISE COMMUNICATIONS
In vitro activity of cefpirome and vancomycin in combination against
gentamicin-susceptible and gentamicin-resistant Staphylococcus aureus
A. Carricajo1

, R. Vermesch2 and G. Aubert1
1Department of Bacteriology and 2Intensive Care Unit, Hopital Bellevue, CHU Saint Etienne,
42055 Saint Etienne Cedex 02, France
Tel: þ33 4 77 12 77 35 Fax: þ33 4 77 12 05 45 E-mail: anne.carricajo@univ-st-etienne.fr
Accepted 15 February 2001
Vancomycin is universally accepted as the first-line drug in the
treatment of methicillin-resistant Staphylococcus aureus (MRSA).
Combination with a cephalosporin such as cefpirome may be
extremely useful in cases of suspected mixed infections. The
aim of this study was to evaluate, using a time kill method, the
vancomycin–cefpirome combination against clinical isolates
of MRSA, including gentamicin-resistant and the gentamicin-
susceptible MRSA strains that are currently highly prevalent
among MRSA isolates [1].
Three clinical methicillin-resistant strains of S. aureus (MRSA)
(mecA gene-positive) isolated in 1997 were studied: one was
kanamycin and tobramycin resistant but gentamicin susceptible
(GS-MRSA) and two were resistant to all the aminoglycosides
tested (kanamycin, tobramycin and gentamicin) (GR-MRSA).
In addition, the three strains were resistant to erythromycin,
lincomycin, tetracycline and pefloxacin and susceptible to tri-
methoprim–sulfamethoxazole, vancomycin and teicoplanin.
One of the GR-MRSA strains was homogeneously methicillin
resistant on the basis of disk sensitivity testing at 378C using
Mueller–Hinton agar, with and without 4% NaCl supplement,
and the two other strains were heterogeneously resistant. The
presence of the mecA gene was assessed using multiplex PCR
amplification [2]. Cefpirome was supplied by Hoechst Marion
Roussel (Romainville, France) and vancomycin by Eli Lilly
(Indianapolis, IN, USA). MICs were determined using the two-
fold serial agar dilution method with Mueller–Hinton medium
(Becton Dickinson, Le Pont-de-Claix, France), supplemented
or not with 4% NaCl for cefpirome. An overnight culture
grown at 358C in Mueller–Hinton broth (Becton Dickinson)
was diluted to 106 colony-forming units (CFU)/mL and ino-
culated, using a multi-inoculator device, on a drug-containing
agar surface. The final inoculum size was approximately
104 CFU per spot. The MIC was defined as the lowest con-
centration of antibiotic allowing growth of less than three co-
lonies on Mueller–Hinton agar after incubation for 48 h at
358C.
Killing curve assays were performed with the two antibiotics,
alone and in combination, at concentrations of 0.25, 0.5, 1, 2
and 4 times the MIC for each strain. These experiments were
performed in glass tubes each containing 10 mL of Mueller–
Hinton broth. An overnight culture in Mueller–Hinton med-
ium was diluted with fresh broth to about 104 CFU/mL. The
same inoculum was added to antibiotic-free Mueller–Hinton
broth as a growth control. After incubation for 4 h at 378C
with shaking, the culture was diluted with fresh broth to about
107 CFU/mL, with and without 4% NaCl supplement, and
antibiotic was added at various concentrations around the MIC.
At fixed times, 0.1 mL of the culture was removed (1, 2, 4, 6, 24
and 48 h) and plated on drug-free Mueller–Hinton agar, with
and without 4% NaCl, after appropriate dilution (101108).
Antibiotic carryover was not a problem, since it occurs only at
higher concentrations [3]. The number of colonies was counted
after 48 h of incubation at 378C and the results plotted on
semilogarithmic graph paper. A bactericidal effect was defined
as a 4 log10 decrease in CFU/mL. Synergy was defined as counts
at least 2 log10 CFU/mL lower after 24 or 48 h of treatment
with the drug combination than with the most active single
drug. The time kill tests were carried out in duplicate for the
three strains.
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Table 1 MICs of vancomycin and cefpirome for the three methicillin-
resistant strains of S. aureus (MRSA) studied by time kill curves
MIC (mg/L)
Isolate Vancomycin Cefpirome
Homogeneous GR-MRSA 1 32a/32b
Heterogeneous GR-MRSA 1 4a/16b
Heterogeneous GS-MRSA 1 4a/16b
aResults without 4%NaCl supplementation. bResults with 4%NaCl supple-
mentation.
The MICs of vancomycin and cefpirome for the three strains
studied by time kill tests are given in Table 1. For the homo-
geneous GR-MRSA strain, time kill curves were plotted with-
out 4% NaCl supplement (Figure 1(a)). This isolate showed a
bactericidal effect at 24 h with 2 MIC vancomycin (2 mg/L) and
with 2 MIC cefpirome (64 mg/L). Synergistic killing was ob-
served at 24 h and 48 h with combined vancomycin (1 MIC ¼
1 mg/L) and cefpirome (1 MIC¼ 32 mg/L). For the hetero-
Figure 1 Time kill curves: (a) vancomycin (VAN) alone, cefpirome (CPO) alone and vancomycin plus cefpirome for the homogeneous GR-MRSA; (b) vanco-
mycin alone, cefpirome alone and vancomycin plus cefpirome for the heterogeneous GR-MRSA; (c) vancomycin alone, cefpirome alone and vancomycin plus
cefpirome for the heterogeneous GS-MRSA.
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geneous strains (Figure 1(b),(c)), time kill curves were plotted
with a 4% NaCl supplement in order to ensure optimal
expression of methicillin resistance. Prior tests were conducted
to verify that the presence of NaCl does not affect the bacter-
icidal properties of vancomycin. The two heterogeneous
MRSA isolates showed a bactericidal effect at 24 h with
4 MIC vancomycin (4 mg/L) and with 2 MIC cefpirome
(32 mg/L). For the GR-MRSA strain, synergistic killing
occurred with combined vancomycin (1 MIC¼ 1 mg/L) and
cefpirome (0.25 MIC¼ 4 mg/L) at 24 h (2 log10 decrease) and
48 h (4 log10 decrease), whereas for the GS-MRSA strain,
synergistic killing was observed only at 48 h with combined
vancomycin (4 MIC¼ 4 mg/L) and cefpirome (0.25 MIC¼
4 mg/L or 0.5 MIC¼ 8 mg/L).
Cefpirome is a cephalosporin with broad-spectrum antibac-
terial activity, including Gram-negative pathogens producing
class I chromosomally mediated b-lactamases. It is also reported
to be more active than third-generation cephalosporins and
cefepime against methicillin-susceptible S. aureus, and some
MRSA strains had MICs within the susceptibility range,
although this is probably not clinically relevant [4]. In our
hospital, we have observed the emergence in recent years of a
new MRSA phenotype characterized by heterogeneous methi-
cillin resistance and gentamicin susceptibility (15% GS-MRSA
strains in 1994 and 90% GS-MRSA strains in 1999), as
described by other authors [5]. We therefore evaluated the in
vitro activity of the cefpirome–vancomycin combination
against GS-MRSA and GR-MRSA. The use of antimicrobial
combination therapy in severe infections is intended to enhance
the therapeutic efficacy for these infections and to decrease the
risk of emerging resistance during treatment. The synergistic
activity of vancomycin and cefpirome has been thoroughly
investigated using in vitro tests: the chequerboard procedure
and the time kill method [3,6,7]. Furthermore, Raymond et al
reported bacteriologic eradication of a mixed infection includ-
ing MRSA and Enterobacter cloacae with this combination [8].
Our results confirm, using the time kill test, the synergistic
activity of both drugs against GR-MRSA and GS-MRSA
with cefpirome concentrations which can be achieved in serum
[8].
In conclusion, the cefpirome–vancomycin combination could
be useful for empirical treatment of suspected mixed infection
involving MRSA and Enterobacteriaceae. However, these
results warrant further evaluation and animal experiments to
determine whether this combination could offer a potential
treatment modality. For GS-MRSA, gentamicin acted syner-
gistically with vancomycin (data not shown) and could be added
to the vancomycin–cefpirome combination. Furthermore,
using an in vitro model and a rabbit model of experimental
endocarditis, Climo et al have recently demonstrated that vanco-
mycin acts synergistically with oxacillin against MRSA having
reduced susceptibility to glycopeptides [9]. Further experiments
are required to determine if the cefpirome– vancomycin combi-
nation may be of particular value in this case too.
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